Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases

Overview

Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional X-ray examinations, computed tomography (CT) and magnetic resonance imaging (MRI). Changes in the size of the metastases is something that is often seen weeks / months after treatment is completed. At Lund University Hospital, a new imaging technique, diffusional variance decomposition (DIVIDE), has now been developed. With this technique, the scatter in isotropic and anisotropic diffusion can be measured for each measuring point, which provides significantly more information about the properties of the tissue compared to current methods.

Full Title of Study: “Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of CNS Metastases”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2023

Interventions

  • Radiation: Brain metastases radiation
    • Brain metastases radiation according to clinical practice.

Arms, Groups and Cohorts

  • Other: Diffusion-weighted MRI to predict treatment response in stereotactic radiotherapy of CNS metastases.
    • Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.

Clinical Trial Outcome Measures

Primary Measures

  • Grade of radiation sensitivity to brain metastasis.
    • Time Frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3×10 Gy.
    • Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Grade of radiation sensitivity to brain metastasis.
    • Time Frame: Is evaluated after 3 months after end of treatment.
    • Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Grade of radiation sensitivity to brain metastasis.
    • Time Frame: Is evaluated after 6 months after end of treatment.
    • Evaluation done by MRI to see whether radiation sensitivity can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Early changes in the tumor during and after completion of radiation therapy.
    • Time Frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3×10 Gy.
    • Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Early changes in the tumor during and after completion of radiation therapy.
    • Time Frame: Is evaluated after 3 months after end of treatment.
    • Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Early changes in the tumor during and after completion of radiation therapy.
    • Time Frame: Is evaluated after 6 months after end of treatment.
    • Evaluation done by MRI to see whether early changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Changes linked to treatment responses.
    • Time Frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3×10 Gy.
    • Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Changes linked to treatment responses.
    • Time Frame: Is evaluated after 3 months after end of treatment.
    • Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Changes linked to treatment responses.
    • Time Frame: Is evaluated after 6 months after end of treatment.
    • Evaluation done by MRI to see whether changes in the tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor.
    • Time Frame: Is evaluated after end of radiotherapy, that is after 3 days, as all subjects receive 3×10 Gy.
    • Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after 3 and 6 months after end of treatment.
  • Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor.
    • Time Frame: Is evaluated after 3 months after end of treatment.
    • Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy after 3 months after end of treatment.
  • Differentiate between radiation damage (radionecrosis) and residual / recurrent tumor.
    • Time Frame: Is evaluated after 6 months after end of treatment.
    • Evaluation done by MRI to see whether differentiation between radionecrosis and residual/recurrent tumor can be measured during radiotherapy and after and 6 months after end of treatment.

Participating in This Clinical Trial

Inclusion Criteria

1. Patients prescribed stereotactic radiation therapy to the brain, where MRI imaging is included in the treatment preparations. 2. Cohesive remaining solid tumor component of ≥10mm. 3. Age ≥18 years. 4. World Health Organisation (WHO) performance status 0-1. Exclusion Criteria:

1. Inability to decide for oneself on participation in the study. 2. Inability to understand the Swedish language. 3. Metastases close to the base of the skull. 4. Contraindications to conducting an MRI examination. 5. Contraindications to obtaining contrast media during MRI examination. 6. Expected survival less than 6 months. 7. Previous radiation treatment to the same site in the brain, i.e. current treatment is a rope radiation. -

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Lund University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Sara Alkner, MD, PhD, +46 46 17 75 20, sara.alkner@med.lu.se

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.